2025 · Bilski — Antioxidant Therapies as Emerging Adjuncts in Rheumatoid Arthritis: Targeting Oxidative Stress to Enhance Treatment Outcomes
Super-Abstract
Rheumatoid arthritis is driven not only by immune dysregulation but also by oxidative stress — current DMARDs fail to address ROS-mediated joint damage, opening space for antioxidant adjuncts. This review covers molecular hydrogen alongside curcumin, resveratrol, NAC, and vitamins as candidate add-on strategies, with a frank assessment that further clinical trials are needed. (International Journal of Molecular Sciences, 2025.)
Commentary
Rheumatoid arthritis (RA) is a chronic autoimmune disease where the synovial joint becomes a site of sustained immune activation, oxidative damage, and progressive cartilage destruction. Standard disease-modifying antirheumatic drugs (DMARDs) — methotrexate, biologics — effectively target immune pathways but do not directly reduce the oxidative component that contributes independently to tissue damage and systemic effects. This review evaluates multiple antioxidant candidates. For H₂ specifically, the authors note its selective neutralisation of the most cytotoxic reactive species (hydroxyl radical, peroxynitrite) without disturbing physiological ROS signalling — a mechanistic advantage over broad antioxidants. The practical appeal is that H₂ might be combined with existing DMARDs without pharmacological interference. However, the authors are explicit: evidence in RA is preliminary, standardised dosing protocols do not exist, long-term safety data are absent, and clinical trials are required.
Key quotes
- „molecular hydrogen (H2) selectively neutralizes harmful ROS, reducing oxidative damage and inflammation.“ — H₂'s proposed mechanism in RA: selective ROS neutralisation without disrupting normal redox signalling
- „oxidative stress as a primary factor in the pathophysiology of rheumatoid arthritis, intensifying inflammatory processes and tissue damage via the overproduction of reactive oxygen species (ROS) and compromised antioxidant defenses.“ — why oxidative stress is a therapeutic target in RA independent of immune pathways
- „further clinical trials are needed to establish standardized dosing, long-term safety, and their integration into current RA treatment protocols.“ — the honest bottom line: no clinical basis for recommendations yet
Our assessment
This is a narrative review, not a clinical trial or meta-analysis. It makes a scientifically coherent case for H₂ as a potential antioxidant adjunct in RA based on its mechanism of action, but the clinical evidence base in rheumatoid arthritis specifically is very thin. The review covers multiple compounds simultaneously, which limits depth for any single agent. The authors' explicit call for clinical trials underscores that this remains an investigational concept. Current findings should not be interpreted as evidence of efficacy in RA patients.
Study design
- Type: narrative review · n: n/a (literature synthesis) · H₂ delivery: hydrogen-rich water (as mentioned in the context of mechanistic studies; no RA-specific H₂ trials quantified)
- Result: oxidative stress identified as independent driver of joint damage in RA; H₂ highlighted for selective ROS neutralisation via hydroxyl radical and peroxynitrite scavenging; evidence from preclinical and mechanistic studies; clinical trial data in RA absent; standardised protocols not yet established
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation and progressive joint destruction. Recent data underscore oxidative stress as a primary factor in the pathophysiology of rheumatoid arthritis, intensifying inflammatory processes and tissue damage via the overproduction of reactive oxygen species (ROS) and compromised antioxidant defenses. Current therapies, including disease-modifying antirheumatic drugs (DMARDs), primarily target immune dysregulation but fail to address oxidative stress, necessitating novel adjunctive treatment strategies. This review explores the potential of antioxidant-based therapies as complementary approaches to RA management. Natural compounds such as curcumin, resveratrol, sulforaphane, and propolis exhibit strong anti-inflammatory and antioxidative properties by modulating redox-sensitive pathways, including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and nuclear factor erythroid 2-related factor 2(Nrf2)/heme oxygenase (HO-1). N-acetylcysteine (NAC) replenishes intracellular glutathione, enhancing cellular resilience against oxidative stress. Additionally, molecular hydrogen (H2) selectively neutralizes harmful ROS, reducing oxidative damage and inflammation. The role of vitamin supplementation (D, B12, C, and K) in regulating immune responses and protecting joint structures is also discussed. This review aims to evaluate the efficacy and potential clinical applications of antioxidant therapies in RA, emphasizing their role in mitigating oxidative damage and improving treatment outcomes. While preliminary findings are promising, further clinical trials are needed to establish standardized dosing, long-term safety, and their integration into current RA treatment protocols.
Source & links
Screenshot of the PubMed page
This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.